- DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development and regulatory approvals, including FDA IDE and PMA pathways
- Full-scale entry into North America, the world's largest bone graft substitute market; strategic partnership to expand in orthopaedics and bone regeneration sectors
SEOUL, South Korea, May 27, 2026 /PRNewswire/ -- CGBIO, a regenerative medicine company (CEO: Hyunseung Yu), announced that it has entered into a global clinical development and exclusive commercialization agreement with DePuy Synthes, a global orthopaedics solutions company, for the NOVOSIS bone graft substitute product portfolio in the United States, Canada, and Australia.
